2. Search Result
Search Result
Results for "

Leptin

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

23

Peptides

7

Natural
Products

10

Recombinant Proteins

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10108
    LY294002
    Maximum Cited Publications
    1119 Publications Verification

    		 PI3K Casein Kinase DNA-PK Apoptosis Autophagy Infection Cancer
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator .
    LY294002
  • HY-10108A
    LY294002 hydrochloride
    Maximum Cited Publications
    1119 Publications Verification

    		 PI3K Casein Kinase DNA-PK Apoptosis Cancer
    LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
    LY294002 hydrochloride
  • HY-P10746
    EB1002

    		Neurokinin Receptor Metabolic Disease
    EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes .
    EB1002
  • HY-P1120
    WKYMVm

    WKYMVm-amide; W-Peptide

    		 Formyl Peptide Receptor (FPR) PERK Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor .
    WKYMVm
  • HY-P3212
    Allo-aca
    Maximum Cited Publications
    10 Publications Verification

    		 Neuropeptide Y Receptor Others Cancer
    Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models .
    Allo-aca
  • HY-12642
    Diethylcarbamazine citrate
    1 Publications Verification

    		 Parasite Bacterial TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Diethylcarbamazine citrate is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine citrate reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine citrate reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine citrate enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine citrate can be used for the researches of bronchial asthma, insulin resistance and infection .
    Diethylcarbamazine citrate
  • HY-B0283
    Acipimox
    2 Publications Verification

    K-9321

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox
  • HY-121515
    DPM-1001

    		Phosphatase Metabolic Disease
    DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property .
    DPM-1001
  • HY-N2217
    Rotundic acid

    		Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid
  • HY-P10927A
    BRP TFA

    BRINP2-related peptide TFA

    		 PKA AP-1 Metabolic Disease
    BRP (BRINP2-related peptide) TFA is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP TFA induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP TFA exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP TFA is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP TFA is applicable to obesity-related research .
    BRP TFA
  • HY-126956
    Porphyra 334

    		Reactive Oxygen Species (ROS) MMP Collagen PPAR DNA/RNA Synthesis Apoptosis Caspase Metabolic Disease Inflammation/Immunology
    Porphyra 334 is a carnosine-like amino acid and a natural photoprotective agent and antioxidant. Porphyra-334 exerts its photoprotective effects by scavenging ROS, inhibiting the expression and activity of MMP-1/8, and promoting the synthesis of collagen and elastin. Porphyra 334 effectively inhibits linoleic acid oxidation induced by alkyl radicals (AAPH) and singlet oxygen. Porphyra 334 has anti-obesity potential by inhibiting the expression of PPARγ2 and C/EBPα. Porphyra 334 protects cells against UV-induced DNA damage and apoptosis by inhibiting the activation of caspase-3 .
    Porphyra 334
  • HY-120327
    KY-226
    2 Publications Verification

    		 Phosphatase Neurological Disease Metabolic Disease
    KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
    KY-226
  • HY-P10927
    BRP

    BRINP2-related peptide

    		 AP-1 PKA Metabolic Disease
    BRP is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP is independent of the leptin, GLP-1 receptor and melanocortin 4 receptor pathways. BRP is applicable to obesity-related research .
    BRP
  • HY-19870C
    Setmelanotide monoacetate
    5+ Cited Publications

    RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

    		 Melanocortin Receptor Calmodulin AMPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a Ki value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .
    Setmelanotide monoacetate
  • HY-135115
    Oleuropein Aglycone

    3,4-DHPEA-EA

    		 α-synuclein HDAC Adrenergic Receptor Inflammation/Immunology
    Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-P1523
    Leptin (22-56), human

    		iGluR Metabolic Disease
    Leptin (22-56), human is the fragment of leptin, mediated via several isoforms of receptors (Ob-Rs).
    Leptin (22-56), human
  • HY-P1304
    CART(55-102)(human)

    		Neuropeptide Y Receptor Neurological Disease
    CART(55-102)(human) is an endogenous satiety factor with potent appetite-suppressing activity. CART(55-102)(human) is closely associated with leptin and neuropeptide Y .
    CART(55-102)(human)
  • HY-P1305
    CART(55-102)(rat)

    		Neuropeptide Y Receptor Neurological Disease
    CART(55-102)(rat) is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) can induces anxiety and stress-related behavior .
    CART(55-102)(rat)
  • HY-N14035
    Garcinia cambogia extract

    		FABP PPAR Metabolic Disease
    Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .
    Garcinia cambogia extract
  • HY-12642A
    Diethylcarbamazine
    1 Publications Verification

    		 Parasite Bacterial TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Diethylcarbamazine is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine can be used for the researches of bronchial asthma, insulin resistance and infection .
    Diethylcarbamazine
  • HY-P10397
    YHIEPV

    rALP-2, Rubisco anxiolytic-like peptide 2

    		 iGluR Neurological Disease Metabolic Disease
    YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects .
    YHIEPV
  • HY-W044525
    Phyllodulcin

    		Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology
    Phyllodulcin is an orally active sweetener found in Hydrangea macrophylla var. thunbergii. Phyllodulcin acts as a non-selective phosphodiesterase inhibitor and exerts anti-allergic effects by suppressing lymphocyte activation. Phyllodulcin can be used to combat obesity by regulating levels of leptin, fat browning-related genes, and hypothalamic BDNF-TrkB signaling .
    Phyllodulcin
  • HY-101764
    Lintitript

    SR 27897

    		 Cholecystokinin Receptor Metabolic Disease
    Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
    Lintitript
  • HY-110218
    CW 008
    2 Publications Verification

    		 PKA Epigenetic Reader Domain Others
    CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
    CW 008
  • HY-P3342
    [D-Leu-4]-OB3

    		PD-1/PD-L1 Apoptosis Inflammation/Immunology
    [D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes .
    [D-Leu-4]-OB3
  • HY-101393A
    CGP 12177 hydrochloride

    (±)-CGP 12177 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    CGP 12177 ((±)-CGP 12177) hydrochloride is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 hydrochloride is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 hydrochloride exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 hydrochloride regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 hydrochloride can be used for cardiovascular and metabolic disease research [1][2][3][4].
    CGP 12177 hydrochloride
  • HY-P3691
    CART (1-39), Human

    		Neuropeptide Y Receptor Neurological Disease
    CART (1-39), Human, Rat is a neuropeptide consisting of 1-39 residues of the CART peptide. CART (1-39), Human, Rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (1-39), Human, Rat inhibits both normal and starvation-induced feeding. CART (1-39), Human, Rat can induce anxiety and stress-related behavior .
    CART (1-39), Human
  • HY-P1304A
    CART(55-102)(human) TFA

    		Neuropeptide Y Receptor Neurological Disease
    CART(55-102)(human) TFA is a human satiety factor with potent appetite-suppressing activity. CART(55-102)(human) TFA is closely associated with leptin and neuropeptide Y .
    CART(55-102)(human) TFA
  • HY-P3692
    CART (55-76), rat

    		Neuropeptide Y Receptor Neurological Disease
    CART (55-76), rat is a neuropeptide (55-76 residues of the CART peptide) and constitutes the N-terminal fragments of CART (55-102). CART (55-76), rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (55-76), rat can induce anxiety and stress-related behavior .
    CART (55-76), rat
  • HY-P3212A
    Allo-aca TFA

    		Neuropeptide Y Receptor Cancer
    Allo-aca TFA, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca TFA blocks leptin signaling and action in numerous in vitro and in vivo models .
    Allo-aca TFA
  • HY-P3341
    OB3

    		Neuropeptide Y Receptor Metabolic Disease Inflammation/Immunology Cancer
    OB3, a derivative of Leptin, show more effective than leptin in reducing obesity and diabetes in mouse models. OB3 can reduce Leptin-related inflammation and proliferation in hepatocellular carcinoma cells .
    OB3
  • HY-P3340
    Leptin (116-130)

    		iGluR Neurological Disease
    Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .
    Leptin (116-130)
  • HY-B0283A
    Acipimox sodium

    K-9321 sodium

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox sodium
  • HY-12192
    A-423579

    		Histamine Receptor Metabolic Disease
    A-423579 is an orally active non-imidazole histamine H3 receptor antagonist. A-423579 exhibits high affinity and good selectivity for human and rat H3 receptors, and possesses both antagonistic and inverse agonistic activities. A-423579 can effectively reduce body weight in obese rodents, with concomitant decreases in fat content, plasma leptin levels, and triglycerides. A-423579 possesses anti-obesity activity and can be used in the research of obesity and related metabolic disorders .
    A-423579
  • HY-101393
    CGP 12177

    (±)-CGP 12177

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    CGP 12177 ((±)-CGP 12177) is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 can be used for cardiovascular and metabolic disease research .
    CGP 12177
  • HY-10108R
    LY294002 (Standard)

    		Reference Standards PI3K Casein Kinase DNA-PK Apoptosis Autophagy Infection Cancer
    LY294002 (Standard) is the analytical standard of LY294002. This product is intended for research and analytical applications. LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator .
    LY294002 (Standard)
  • HY-N16527
    7-O-Galloyl-D-sedoheptulose

    		TNF Receptor Interleukin Related NADPH Oxidase Reactive Oxygen Species (ROS) NF-κB COX NO Synthase JNK AP-1 TGF-β Receptor Metabolic Disease
    7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound. 7-O-Galloyl-D-sedoheptulose lowers the serum levels of glucose, leptin, insulin, C-peptide, resistin, TNF-α, IL-6, and increases the serum level of adiponectin. 7-O-Galloyl-D-sedoheptulose significantly reduces the levels of ROS and lipid peroxidation products (TBARS) by down-regulating the protein expression of NADPH oxidase subunit Nox-4 and p22phox. 7-O-Galloyl-D-sedoheptulose down-regulates NF-κB and related pro-inflammatory factors (COX-2, iNOS), inhibits the phosphorylation of JNK and the activity of its downstream AP-1. 7-O-Galloyl-D-sedoheptulose reduces the expression of TGF-β1 and fibronectin, indicating its potential in anti-tissue fibrosis. 7-O-Galloyl-D-sedoheptulose can be used for the study of type 2 diabetes and its hepatic and pancreatic complications .
    7-O-Galloyl-D-sedoheptulose
  • HY-P1305A
    CART(55-102)(rat) TFA

    		Neuropeptide Y Receptor Neurological Disease
    CART(55-102)(rat) TFA is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) TFA is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) TFA can induces anxiety and stress-related behavior .
    CART(55-102)(rat) TFA
  • HY-151963
    PPARγ/GR modulator 1

    		PPAR Glucocorticoid Receptor Metabolic Disease
    PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with Kis of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .
    PPARγ/GR modulator 1
  • HY-B0283R
    Acipimox (Standard)

    K-9321 (Standard)

    		 Carbonic Anhydrase Reference Standards Metabolic Disease
    Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox (Standard)
  • HY-160514
    LXQ46

    		Phosphatase Metabolic Disease
    LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models .
    LXQ46
  • HY-P1120A
    WKYMVm TFA

    		Formyl Peptide Receptor (FPR) PERK Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    WKYMVm (TFA) is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor .
    WKYMVm TFA
  • HY-N2217R
    Rotundic acid (Standard)

    		Reference Standards Akt mTOR p38 MAPK Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Rotundic acid (Standard) is the analytical standard of Rotundic acid (HY-N2217). This product is intended for research and analytical applications. Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid (Standard)
  • HY-12642AR
    Diethylcarbamazine (Standard)

    		Reference Standards Parasite Bacterial TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Diethylcarbamazine (Standard) is the analytical standard of Diethylcarbamazine (HY-12642A). This product is intended for research and analytical applications. Diethylcarbamazine is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine can be used for the researches of bronchial asthma, insulin resistance and infection .
    Diethylcarbamazine (Standard)
  • HY-12642R
    Diethylcarbamazine citrate (Standard)

    		Reference Standards Parasite Bacterial TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Diethylcarbamazine citrate (Standard) is the analytical standard of Diethylcarbamazine citrate (HY-12642). This product is intended for research and analytical applications. Diethylcarbamazine citrate is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine citrate reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine citrate reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine citrate enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine citrate can be used for the researches of bronchial asthma, insulin resistance and infection .
    Diethylcarbamazine citrate (Standard)
  • HY-10108AR
    LY294002 hydrochloride (Standard)

    		Reference Standards PI3K Casein Kinase DNA-PK Apoptosis Cancer
    LY294002 (hydrochloride) (Standard) is the analytical standard of LY294002 (hydrochloride). This product is intended for research and analytical applications. LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
    LY294002 hydrochloride (Standard)
  • HY-101764R
    Lintitript (Standard)

    SR 27897 (Standard)

    		 Reference Standards Cholecystokinin Receptor Metabolic Disease
    Lintitript (Standard) (SR 27897 (Standard)) is the analytical standard of Lintitript (HY-101764). This product is intended for research and analytical applications. Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
    Lintitript (Standard)
  • HY-N19725
    Calonysterone

    		Interleukin Related Metabolic Disease
    Calonysterone is an orally effective IL-6 inhibitor. Calonysterone reduces the level of the proinflammatory cytokine IL-6. Calonysterone prevents diet-induced obesity. Calonysterone normalizes abnormal plasma adiponectin and leptin concentrations. Calonysterone increases the percentage of total DNA methylation. Calonysterone enhances antioxidant activity. Calonysterone is applicable to obesity-related research .
    Calonysterone
  • HY-P11588
    KBP-042

    		Amylin Receptor CGRP Receptor Metabolic Disease
    KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance .
    KBP-042
  • HY-N19818
    Glycybridin C

    		Phosphatase NF-κB Pregnane X Receptor (PXR) Cancer
    Glycybridin C is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor and pregnane X receptor (PXR) ligand. Glycybridin C inhibits insulin and leptin signaling pathway negative regulation, LPS (HY-D1056)-induced NF-κB transcriptional activity. Glycybridin C forms hydrophobic and π-π stacking interactions with Met243, Phe288, Tyr306, and His407 residues of PXR. Glycybridin C can be used for the research of hepatocellular carcinoma, colorectal adenocarcinoma, breast carcinoma .
    Glycybridin C

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: